Quick Answer
Dogwood Therapeutics, Inc. reported R&D Expense of $21.87 million for fiscal year 2025.
Dogwood Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $21.87M | +519.3% |
| 2024 | $3.53M | +104.3% |
| 2023 | $1.73M | -78.6% |
| 2022 | $8.07M | -25.3% |
| 2021 | $10.80M | +5464.4% |
| 2020 | $194.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.52M | +2613.4% | +465.0% |
| June 30, 2025 | $2.57M | +664.7% | +5.5% |
| March 31, 2025 | $2.44M | +609.0% | +355.4% |
| September 30, 2024 | $535.2K | +43.0% | +59.2% |
| June 30, 2024 | $336.1K | -39.8% | -2.2% |
| March 31, 2024 | $343.7K | -30.9% | -8.1% |
| September 30, 2023 | $374.2K | -76.9% | -32.9% |
| June 30, 2023 | $557.8K | -76.8% | +12.1% |
- Dogwood Therapeutics, Inc. showed an increase of +519.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Dogwood Therapeutics, Inc.’s r&d expense has grown by 11170.4% (from $194.0 thousand to $21.87 million).
- The most recent figure is from Dogwood Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: